Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 52, n° 3S
page P2 (mars 2005)
Doi : 10.1016/j.jaad.2004.10.024
Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis
 

Richard Langley, MD, Dalhousie University, Halifax, NS, Canada; Craig Leonardi, MD, Central Dermatology, St. Louis, MO, United States; Darryl Toth, MD, Probity Medical Research, Windsor, ON, Canada; Diana Chen, MD, Abbott Laboratories, Abbott Park, IL, United States


 P8
Drs. Langley, Leonardi, and Toth are primary investigators for Abbott Laboratories. Dr. Chen is employed by Abbott Laboratories.
100 percent sponsored by Abbott Laboratories


Top of the page

© 2005  American Academy of Dermatology, Inc.@@#104156@@